Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial of Belimumab Combined With Multi-target Induction Therapy in Adult Patients With Severe Lupus Nephritis

NCT05863936 is registered in ClinicalTrials.gov with Nanjing University School of Medicine as lead sponsor.

NCT NCT05863936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05863936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial of Belimumab Combined With Multi-target Induction Therapy in Adult Patients With Severe Lupus Nephritis
Lead sponsor
Nanjing University School of Medicine
Phase
Phase 3
Overall status
Unknown status
Start date
April 1, 2023
Completion date
December 31, 2024
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis, remission, safety issues